Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

PURPOSE: We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a rare, aggressive, and highly lethal malignancy with poor patient outcomes and no systemic therapies with clinical benefit. M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Subbiah, Vivek, Kreitman, Robert J., Wainberg, Zev A., Cho, Jae Yong, Schellens, Jan H.M., Soria, Jean Charles, Wen, Patrick Y., Zielinski, Christoph, Cabanillas, Maria E., Urbanowitz, Gladys, Mookerjee, Bijoyesh, Wang, Dazhe, Rangwala, Fatima, Keam, Bhumsuk
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2018
Témata:
RAPID COMMUNICATION
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791845/
https://ncbi.nlm.nih.gov/pubmed/29072975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.6785
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky